TR201713954A2 - Tenofovir, emtrisitabin ve efavirenzin farmasötik kombinasyonlari - Google Patents

Tenofovir, emtrisitabin ve efavirenzin farmasötik kombinasyonlari Download PDF

Info

Publication number
TR201713954A2
TR201713954A2 TR2017/13954A TR201713954A TR201713954A2 TR 201713954 A2 TR201713954 A2 TR 201713954A2 TR 2017/13954 A TR2017/13954 A TR 2017/13954A TR 201713954 A TR201713954 A TR 201713954A TR 201713954 A2 TR201713954 A2 TR 201713954A2
Authority
TR
Turkey
Prior art keywords
tenofovir
emtrisitabin
eavirenzine
pharmaceutical combinations
pharmaceutically acceptable
Prior art date
Application number
TR2017/13954A
Other languages
English (en)
Inventor
Demi̇r Bülent
Baş Oğuz
Türkyilmaz Ali̇
Yildirim Edi̇z
Muratoğlu Yeşi̇m
Atmaca İbrahi̇m
Original Assignee
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi filed Critical Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
Priority to TR2017/13954A priority Critical patent/TR201713954A2/tr
Priority to EP18840094.9A priority patent/EP3684341A2/en
Priority to PCT/TR2018/050508 priority patent/WO2019059868A2/en
Publication of TR201713954A2 publication Critical patent/TR201713954A2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Abstract

Mevcut buluş, tenofovir veya onun farmasötik olarak kabul edilebilir bir tuzunu, emtrisitabin veya onun farmasötik olarak kabul edilebilir bir tuzunu ve efavirenz veya onun farmasötik olarak kabul edilebilir bir tuzunu içeren çentikli bir çift katmanlı tablet ile ilgilidir.
TR2017/13954A 2017-09-20 2017-09-20 Tenofovir, emtrisitabin ve efavirenzin farmasötik kombinasyonlari TR201713954A2 (tr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
TR2017/13954A TR201713954A2 (tr) 2017-09-20 2017-09-20 Tenofovir, emtrisitabin ve efavirenzin farmasötik kombinasyonlari
EP18840094.9A EP3684341A2 (en) 2017-09-20 2018-09-19 Pharmaceutical combinations of tenofovir, emtricitabine and efavirenz
PCT/TR2018/050508 WO2019059868A2 (en) 2017-09-20 2018-09-19 PHARMACEUTICAL COMBINATIONS OF TENOFOVIR, EMTRICITABINE AND EFAVIRENZ

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TR2017/13954A TR201713954A2 (tr) 2017-09-20 2017-09-20 Tenofovir, emtrisitabin ve efavirenzin farmasötik kombinasyonlari

Publications (1)

Publication Number Publication Date
TR201713954A2 true TR201713954A2 (tr) 2019-04-22

Family

ID=65237119

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2017/13954A TR201713954A2 (tr) 2017-09-20 2017-09-20 Tenofovir, emtrisitabin ve efavirenzin farmasötik kombinasyonlari

Country Status (3)

Country Link
EP (1) EP3684341A2 (tr)
TR (1) TR201713954A2 (tr)
WO (1) WO2019059868A2 (tr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114948970A (zh) * 2022-06-07 2022-08-30 安徽贝克生物制药有限公司 含依非韦伦的药物组合物及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3025718A1 (en) 2003-01-14 2016-06-01 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
TWI471145B (zh) * 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) * 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
WO2008096369A2 (en) * 2007-02-05 2008-08-14 Matrix Laboratories Limited Pharmaceutical formulation for use in hiv therapy

Also Published As

Publication number Publication date
EP3684341A2 (en) 2020-07-29
WO2019059868A2 (en) 2019-03-28
WO2019059868A3 (en) 2019-04-25

Similar Documents

Publication Publication Date Title
PH12017502431A1 (en) Pharmaceutical formulations comprising tenofovir and emtrictabine
CY1123571T1 (el) Βουπροπιονη για τη ρυθμιση των φαρμακευτικων επιπεδων δεξτρομεθορφανης στο πλασμα
CY1124007T1 (el) Στοματικες δοσολογικες μορφες παρατεταμενης απελευθερωσης τοφασιτινιμπης
EA201792591A1 (ru) Фармацевтические препараты
CY1121999T1 (el) Φαρμακοτεχνικες μορφες συνδυασμου δαρουναβιρης
EA201390662A1 (ru) Фармацевтическая композиция, содержащая дутастерид
TR201916829A2 (tr) Dapagli̇flozi̇n ve metformi̇n i̇çeren çi̇ft katmanli tablet formülasyonlari
CY1119446T1 (el) Φαρμακοτεχνικες μορφες δαρουναβιρης
EA201491517A1 (ru) N-этил-n-фенил-1,2-дигидро-4,5-дигидрокси-1-метил-2-оксо-3-хинолинкарбоксамид, его получение и применения
EA202090542A1 (ru) Высококонцентрированные лекарственные формы придопидина
MX2016002560A (es) Forma de dosificacion unitaria que comprende emtricitabina, tenofovir, darunavir y ritonavir y un comprimido monolitico que comprende darunavir y ritonavir.
EA202090913A1 (ru) Композиция таблеток с модифицированным высвобождением, содержащая мирабегрон
TR201713954A2 (tr) Tenofovir, emtrisitabin ve efavirenzin farmasötik kombinasyonlari
TR201721700A2 (tr) Saksagli̇pti̇ni̇n ağizda dağilan formülasyonlari
CY1120192T1 (el) Ενωσεις για την ενισχυση της γνωστικης λειτουργιας
EA201991286A1 (ru) Твердая фармацевтическая композиция для перорального применения, содержащая тенофовир и эмтрицитабин
TR201619184A2 (tr) Donepezi̇l ve memanti̇n i̇çeren kapsül bi̇leşi̇mleri̇
TR201914043A1 (tr) Dapagli̇flozi̇n ve metformi̇n i̇çeren efervesan tablet formülasyonlari
TR201007926A1 (tr) Prasugrel tablet formülasyonları.
EA201691422A1 (ru) Перорально распадающиеся таблетированные составы мемантина
EA201991007A1 (ru) Твердые фармацевтические композиции на основе гидрохлорида луразидона для перорального применения
TR201721824A2 (tr) Li̇nagli̇pti̇n ve metformi̇n i̇çeren modi̇fi̇ye salim sağlayan kombi̇nasyon
JOP20170198A1 (ar) صيغ صيدلية تشتمل على تينوفوفير و إيمترايسيتابين
CY1123966T1 (el) Διαδικασια για την παρασκευη νατριουχου εποπροστενολης ενισχυμενης σταθεροτητας
IN2013MU03370A (tr)